再鼎医药(09688.HK) (ZLAB.US) 宣布，国家医疗保障局发布的2024国家医保药品目录已更新，并将公司旗下“奥凯乐”(瑞普替尼)纳入到新版国家医保药品目录当中，用于治疗ROS1阳性的局部晚期或转移性非小细胞肺癌成人患者。
另外，集团的“纽再乐”(奥马环素)静脉输注剂型及“擎乐”(瑞派替尼)在今次目录更新中成功续约，分别用于治疗患有社区获得性细菌性肺炎和急性细菌性皮肤和皮肤结构感染的成人患者，以及既往接受过3种或以上激酶抑制剂的晚期胃肠间质瘤成人患者。
再鼎医药大中华区首席商务官朱彤表示，期望今年底前上市奥凯乐，预期奥凯乐的纳入、纽再乐和擎乐的续约，将进一步帮助国内的患者以更可负担的费用接受治疗。公司总裁兼首席营运官Josh Smiley指，再鼎目前已有六种产品被纳入国家医保目录，未来将继续配合国家医保局的工作，提高差异化创新疗法在中国的可负担性和可及性。(gc/k)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-28 12:25。) (美股为即时串流报价； OTC市场股票除外，资料延迟最少15分钟。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.